TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Sponsor: Tvardi Therapeutics, Incorporated · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 193 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,788,170

Rescue Site Savings

+$1,845,690

Unlock Full NCT05440708 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05440708 Rescue Dossier →